Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Who May Qualify: - Pathologically confirmed Hodgkin Lymphoma according World Health Organization (WHO) classification. - Patient is ≥ 18 years of age at the time of signing the willing to sign a consent form form (ICF). - Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted. - Patient is willing and able to adhere to the study visit schedule and other protocol requirements. - Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below). - Meet the following lab criteria: Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma); platelet count at least 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma); blood count (hemoglobin) at least 8 g/dL. - Anticipated expected to live at least 3 months. Who Should NOT Join This Trial: - Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. - Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy. - Pregnant or lactating women. Always talk to your doctor about whether this trial is right for you.